FindTrial
Sign In

Effect of Vitamin B12, Folate, and Entacapone in Levodopa-induced hyperhomocysteinemia

Effect of Vitamin B12, Folate, and Entacapone in Levodopa-induced hyperhomocysteinemia

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
TCTR
Registry ID
TCTR20181221001
Enrollment
62
Registered
2018-12-21
Start date
2019-01-02
Completion date
Unknown
Last updated
2026-08-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Parkinson&#39

Interventions

Take 12 weeks of vitamin B12 0.5 mg plus folate 5 mg ,Take 12 weeks of entacapone titrate up to at least 600 mg/day,Control group No intervention
Active Comparator Dietary Supplement,Active Comparator Drug,No Intervention No treatment
vitamin B12 plus folate,entacapone,No intervention

Sponsors

Research and Development Center, Prapokklao Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 90 Years

Inclusion criteria

Inclusion criteria: The PD patients who are being treated with levodopa at least 300 mg/day for at least 1 year.

Exclusion criteria

Exclusion criteria: 1. Patients who are being treated with entacapone 2. Patients who are taking vitamin B12 or folate supplement. 3. Presence of the conditions influence homocysteine level are end stage renal disease, liver cirrhosis, smoking, malignancy, dementia, diabetes mellitus, hypothyroid, take thaizide diuretic, azathioprine, phenytoin, metrotrexate

Design outcomes

Primary

MeasureTime frame
Serum homocysteine level at weeks 6 and 12 after treatment Blood testing—

Secondary

MeasureTime frame
N/A N/A N/A—

Countries

Thailand

Contacts

Public ContactChumpol Anamnart

Prapokklao Hospital

tom_ppk@yahoo.com0814306100

Outcome results

None listed

Source: TCTR (via WHO ICTRP) · Data processed: Aug 9, 2026